516% Jump for Intercept Pharmaceuticals, Unknown Biotech With Unlikely Outcome

Intercept Pharmaceuticals jumps on phase 2 data for obeticholic acid in patients with NASH.

Jan 10, 2014 at 6:00PM

Sometimes it takes big news to get a biotech on investors' radar. It doesn't get much bigger than the more than 500% jump that Intercept Pharmaceuticals (NASDAQ:ICPT) has had over the past two days.

You're excused if you've never heard of Intercept Pharmaceuticals. The company only IPOed a little more than a year ago. If you're like me, you tend to ignore IPOs, figuring there's plenty of time to get to know the company.

Intercept IPOed at $15; it's now around $445. Oops.

Why all the fuss?
Being an unknown biotech can keep a company undervalued, but big moves require an unexpected catalyst. In Intercept's case, few people -- not even company executives -- were expecting that the company's lead drug, obeticholic acid, would pass its phase 2 study in nonalcoholic steatohepatitis, or NASH, at the interim peek at the data. Most investors were focused on the phase 3 trial in primary biliary cirrhosis, another liver disease.

To be stopped early, the trial had to reach a p-value of less than 0.0031; or put another way, there's a 0.31% chance that the difference between the improvement by patients taking obeticholic acid and those taking placebo happened by chance alone.

The company didn't release the full data -- it doesn't even have the data yet since the trial was run by collaborators at the National Institute of Diabetes & Digestive & Kidney Diseases -- but at this point, it doesn't really matter. The drug is clearly working given the highly statistically significant improvement.

NASH is one of the last large untapped markets. There's no approved drugs for the disease, and more than 6 million Americans may have NASH that has advanced far enough that they're in danger of needing a liver transplant in the not-too-distant future. It's not hard to get to billions of sales when you start with millions of patients.

Interested yet?
The next step for Intercept is to obtain the data, and see if it is sufficient to get an accelerated approval, or if the FDA will want a larger phase 3 trial. Intercept's collaborator Dainippon Sumitomo Pharma is running a NASH trial in Japan that's supposed to read out by the end of next year. If the FDA allowed that trial to substitute for a pre-approval trial run by Intercept, it would shave years off the approval time.

A couple of things still need to go right to justify Intercept's lofty valuation. NASH is currently diagnosed by liver biopsy. That's not really practical to identify those 6 million potential patients. A diagnostic will increase the realistic market size substantially.

Second, obeticholic acid isn't without competition. While there aren't any approved drugs for NASH, Conatus Pharmaceuticals (NASDAQ:CNAT), Gilead Sciences (NASDAQ:GILD), and Isis Pharmaceuticals (NASDAQ:ISIS) all have drugs being tested as treatments for the disease. Being first is helpful for grabbing the market, but the best drugs usually win out. If Conatus, Gilead, or Isis can improve NASH faster, better, with fewer side effects, or cheaper, they could eat into Intercept's potential market.

Two game-changing biotechs
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information